Delving into the Latest Updates on Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

主要目的：评价SAK2001在晚期实体瘤受试者中的安全性和耐受性，并观察该药的剂量限制性毒性（DLT），确定其在人体中的最大耐受剂量（MTD），为后续临床研究提供剂量选择依据；次要目的：评价SAK2001在晚期实体瘤受试者中的药代动力学（PK）特征；初步评价SAK2001在晚期实体瘤受试者中的抗肿瘤疗效；比较SAK2001与多西他赛注射液（泰索帝®）的PK特征、安全性和抗肿瘤疗效。

[Translation]

Primary purpose: To evaluate the safety and tolerability of SAK2001 in subjects with advanced solid tumors, observe the dose-limiting toxicity (DLT) of the drug, determine its maximum tolerated dose (MTD) in humans, and provide a basis for dose selection for subsequent clinical studies; Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of SAK2001 in subjects with advanced solid tumors; To preliminarily evaluate the anti-tumor efficacy of SAK2001 in subjects with advanced solid tumors; To compare the PK characteristics, safety and anti-tumor efficacy of SAK2001 with docetaxel injection (Taxotere®).

Start Date31 Mar 2023

Sponsor / Collaborator

Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data